- Therapeutic Dina (NASDAQ:DIN) announced Tuesday that the U.S. Food and Drug Administration (FDA) issued a fast-track designation for DYNE-101, an experimental therapy for a rare muscle disorder called myotonic dystrophy type 1 (DM1).
- DYNE-101, a drug with orphan drug designation in the